A Retrospective Study of Risk of Cardiovascular Events in users of Antimuscarinic Drugs to treat Overactive Bladder (OAB)
Latest Information Update: 14 May 2018
At a glance
- Drugs Solifenacin (Primary) ; Darifenacin; Fesoterodine; Oxybutynin; Tolterodine; Trospium chloride
- Indications Overactive bladder
- Focus Therapeutic Use
Most Recent Events
- 14 May 2018 New trial record
- 03 May 2018 Results published in the Pharmacotherapy